A detailed history of Raleigh Capital Management Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 212 shares of VRTX stock, worth $102,160. This represents 0.04% of its overall portfolio holdings.

Number of Shares
212
Previous 50 324.0%
Holding current value
$102,160
Previous $20,000 340.0%
% of portfolio
0.04%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$407.69 - $446.08 $66,045 - $72,264
162 Added 324.0%
212 $88,000
Q4 2023

Feb 21, 2024

BUY
$343.0 - $410.68 $10,290 - $12,320
30 Added 150.0%
50 $20,000
Q3 2023

Dec 06, 2023

BUY
$338.18 - $362.46 $338 - $362
1 Added 5.26%
20 $6,000
Q1 2023

May 22, 2023

BUY
$283.23 - $323.1 $5,381 - $6,138
19 New
19 $5,000
Q1 2022

May 12, 2022

SELL
$221.42 - $260.97 $885 - $1,043
-4 Closed
0 $0
Q4 2021

Feb 16, 2022

BUY
$177.01 - $223.45 $708 - $893
4 New
4 $1,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $124B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Raleigh Capital Management Inc. Portfolio

Follow Raleigh Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raleigh Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raleigh Capital Management Inc. with notifications on news.